Constant's lead drug candidate, TXA127, is a pharmaceutical formulation of the natural human peptide, angiotensin-(1-7) [Ang-(1-7)]. COVID-19 Program: TXA127 is uniquely positioned at the intersection of two current views of COVID-19: 1. The disease is characterized by a diffuse vasculopathy and 2. The disease is an ACE2/Ang-(1-7) deficiency. TXA127’s mechanism of action addresses much of the pathophysiology of COVID-19 by replacing the lost Ang-(1-7) caused by SARS-CoV-2 binding to ACE2. Recent data shows that the level of Ang-(1-7) is inversely correlated with the severity of COVID-19 disease (Henry, et al. 2020) Ang-(1-7), the active ingredient in Constant’s product, TXA127, has been shown to have multiple biologic effects that are relevant to the treatment of COVID-19. These effects include: -reducing oxidative stress and ROS, -restoring the integrity of epithelial and endothelial surfaces, -reducing inflammation by reversing the increased permeability of the blood vessels caused by the virus; thereby preventing movement of inflammatory cells into tissue leading to the “cytokine storm,” -reducing apoptosis, -inhibiting coagulopathy, and -reducing fibrosis through down-regulation of the TGF beta pathway. Ang-(1-7) has been shown to have positive outcomes in a number of animal models of lung injury, stroke and heart disease. In addition, in several disease models it has become clear that blocking the effect of Ang-(1-7) is detrimental. Constant is involved with 3 investigator-initiated clinical trials: at Columbia University Irving Medical Center in NYC; one sponsored by Bar-Ilan University in Israel using sites at Rambam Health Care Campus in Haifa, Ziv Medical Center in Safed and other medical centers in Galilee; and one other US study at sites to be determined. Combined the 3 studies will recruit over 600 patients, with all studies designed as randomized, placebo-controlled trials. The Columbia and Israel studies are currently recruiting.